Trump Scraps Plans for New Restrictions on Chinese Investment

UPI Top Stories |


President Donald Trump said Wednesday he will rely on Congress updating a 30-year-old law that lets U.S. review foreign investments.

A statement by the president suggested he would not impose new restrictions on Chinese investment in U.S. technology, and will rely on existing tools to guard against purchases and theft of U.S. innovations vital to the economy.



The legislation "will enhance our ability to protect the United States from new and evolving threats posed by foreign investment while also sustaining the strong, open investment environment to which our country is committed and which benefits our economy and our people," Trump said.

Last week, a report suggested the Trump administration is planning to impose restrictions against firms with at least 25 percent Chinese ownership from buying technology companies.

The Wall Street Journal reported the U.S. Treasury is devising new policy to prevent firms where Chinese ownership is at least 25 percent from purchasing "industrially significant technology."

After the announcement, Sen. Marco Rubio, R-Fla. said Trump's plan is a mistake.

"If in fact President Trump is now backtracking on tough limits on Chinese investment, it is a VERY BIG MISTAKE," Rubio tweeted. "#China is strategically buying up U.S. companies specializing in cutting edge technology. What they don't steal from us they buy away from us."

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.